XOMA Royalty Corporation reported over $50 million in cash receipts for 2025, with royalties up 68% year-over-year. The company added 22 assets to its portfolio, completed seven acquisitions generating $11.7 million in non-dilutive capital, and repurchased 648,048 shares for $16 million. Key 2026 catalysts include Phase 2b/3 data readouts and potential EMA regulatory decisions on commercial assets OJEMDA and MIPLYFFA.

Investor rights law firm Halper Sadeh LLC is investigating four companies for potential securities law violations and breaches of fiduciary duties related to their proposed sales. The investigations focus on whether insiders are receiving preferential financial benefits and whether transaction terms may limit competing offers for Day One Biopharmaceuticals, Select Medical Holdings, European Wax Center, and FONAR Corporation.

Servier has agreed to acquire Day One Biopharmaceuticals for $21.50 per share in cash, representing a total equity value of approximately $2.5 billion. The acquisition strengthens Servier's rare oncology portfolio, particularly in pediatric low-grade glioma, and expands its pipeline with programs targeting adult and pediatric cancers. The transaction is expected to close in Q2 2026, subject to customary closing conditions including U.S. antitrust clearance.

Day One Biopharmaceuticals reported strong 2025 financial results with OJEMDA net product revenues of $155.4 million (172% YoY growth) and Q4 revenues of $52.8 million. The company reaffirmed its 2026 U.S. OJEMDA revenue guidance of $225-$250 million and announced the acquisition of Mersana Therapeutics to expand its pipeline with Emi-Le for adenoid cystic carcinoma treatment.

Day One Biopharmaceuticals (NASDAQ: DAWN) has successfully completed its acquisition of Mersana Therapeutics (NASDAQ: MRSN) for $25 per share in cash plus contingent value rights worth up to $30.25 per share. The acquisition adds Emi-Le, a novel antibody-drug conjugate targeting B7-H4 for treating adenoid cystic carcinoma, to Day One's clinical pipeline, expanding its presence in adult oncology while maintaining focus on rare cancers.

Day One Biopharmaceuticals agreed to acquire Mersana Therapeutics for up to $285 million, expanding its oncology pipeline with a focus on developing antibody-drug conjugates targeting cancers, particularly in pediatric and triple-negative breast cancer treatments.

Day One Biopharmaceuticals announced it will acquire Mersana Therapeutics for approximately $129 million, expanding its oncology portfolio with the antibody-drug conjugate emiltatug ledadotin (Emi-Le), which shows early anti-tumor activity in adenoid cystic carcinoma treatment.

Day One Biopharmaceuticals reported Q2 2025 net product revenue of $33.6 million for OJEMDA, a 310% increase from Q2 2024. The company expects full-year 2025 revenue of $140-$150 million and continues advancing its clinical pipeline, including the FIREFLY-2 trial for pediatric low-grade glioma treatment.

The global cancer antibody drug conjugates (ADCs) market is expected to surpass $50 billion by 2030, driven by the approval of 16 ADC drugs and over 500 ADCs in clinical trials. The market has experienced substantial growth, reaching over $7 billion in the first half of 2024, with ADCs offering improved efficacy and lower toxicity compared to traditional cancer treatments.

Day One (DAWN) gains 11% on in-licensing exclusive worldwide rights to MabCare???s MTX-13, which is set to begin clinical studies for adult and pediatric solid tumor indications.

Day One receives exclusive license for development and commercialization of MTX-13 (DAY301), which received IND clearance by the FDA in April 2024

BRISBANE, Calif., May 30, 2024 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN) (“Day One” or the “Company”), a commercial-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced it sold its Priority Review Voucher (PRV) for $108 million to an undisclosed buyer. The Company was awarded the PRV following the U.S. Food and Drug Administration (FDA) accelerated approval of OJEMDA™ (tovorafenib).